9 major insurance companies in Canada approved the reimbursement of the Montméd Timesulin under "standard group policies that include coverage for diabetic supplies".
MONTREAL, Aug. 26, 2014 When it comes to diabetes supplies, innovations are often accused of having very little clinical relevance. But Timesulin happens to answer a real medical need.
Fitting most of insulin disposable pen on the market, Timesulin shows how long it's been since your last injection. One advantage being, indeed, preventing from missed or double insulin doses. Very easy to use, Timesulin starts automatically once it is put back on the insulin pen after an injection. There is no settings or complicated handling needed. Therefore, it enhances safety and eases daily worries for diabetic patients.
According the 2010 Novo Nordisk Gapp study (conducted among almost 3,000 physicians and patients in 8 countries), more than four in 10 people with diabetes say they struggle to effectively control their blood sugar either it is because they forget a dose, fail to take their insulin treatment properly or double their dose. Also, 67% of patients taking insulin are concerned about experiencing a hypoglycemic event in the future.
From a public health perspective, the disease and its treatments can lead to a variety of short-term and long-term complications such as infections, slow wound healing, cardiovascular disease, vision loss, kidney failure, nerve damage, problems with pregnancy, oral disease and so on. Those health issues, as well as diabetes management itself, result in reduced quality of life, work limitations and higher risk of early death. They also greatly increase the need for health care resources and the economic burden of diabetes for society.
Widely used, Timesulin cap could help avoid hypo or hyperglycemic episodes and related complications and reduce future diabetes-related expenditures.
By securing reimbursement for Timesulin, Montméd and insurance companies have shown their understanding of the complexity of care in diabetes and their commitment to diversify the ways to make diabetes management simplermake diabetes management simplermake diabetes management simpler.
"For Montméd, having Timesulin reimbursed by benefit plans was a matter of equality. Since public healthcare coverage in Canada is rather uneven across the country because it is within competences of provinces and territories, we wanted to ensure accessibility to Timesulin for as many diabetics as possible because it can really make a difference in their lives." Gino Henry, General Manager of Montméd for Canada.
Timesulin's reimbursement has been approved by:
| Great West Life Manulife Financiel Sun Life Financial Industrial Alliances Medavie Blue Cross |
Empire Life Standard Life Equitable Life Desjardins
|
About montméd :
Montméd is a Canadian manufacturer and distributor of medical devices within the area of diabetes and self-care. Its range of products includes insulin syringes, pen needles, thermometers, blood pressure monitors, skin care, insulin cooling wallet and so on. Montméd focuses on bringing a unique touch to each of its product, aligned with users' needs. It offers advices, news and educational tools to both patients and health-care professionals through its Health Street program.
The company also provides global distribution and marketing services for other medical equipment firms.
"Simple and unique innovations that make a difference"
Version française disponible sur demande.
Image with caption: "How to obtain Montméd Timesulin® reimbursement? (CNW Group/Montméd)". Image available at: http://photos.newswire.ca/images/download/20140826_C3440_PHOTO_EN_5126.jpg
Image with caption: "Montméd (CNW Group/Montméd)". Image available at: http://photos.newswire.ca/images/download/20140826_C3440_PHOTO_EN_5127.jpg
SOURCE: Montméd
www.montmed.ca, Media contact : Claire GAILLARD, Tel : 1 (514)-622-0933, [email protected]
Share this article